Inflammasomes in neuroinflammatory and neurodegenerative diseases

Sofie Voet\textsuperscript{1,2}, Sahana Srinivasan\textsuperscript{1,2}, Mohamed Lamkanfi\textsuperscript{3,4,*} & Geert van Loo\textsuperscript{1,2,**}

Abstract

Neuroinflammation and neurodegeneration often result from the aberrant deposition of aggregated host proteins, including amyloid-\(\beta\), \(\alpha\)-synuclein, and prions, that can activate inflammasomes. Inflammasomes function as intracellular sensors of both microbial pathogens and foreign as well as host-derived danger signals. Upon activation, they induce an innate immune response by secreting the inflammatory cytokines interleukin (IL)-1\(\beta\) and IL-18, and additionally by inducing pyroptosis, a lytic cell death mode that releases additional inflammatory mediators. Microglia are the prominent innate immune cells in the brain for inflammasome activation. However, additional CNS-resident cell types including astrocytes and neurons, as well as infiltrating myeloid cells from the periphery, express and activate inflammasomes. In this review, we will discuss current understanding of the role of inflammasomes in common degenerative diseases of the brain and highlight inflammasome-targeted strategies that may potentially treat these diseases.

Keywords disease; inflammasome; inflammation; microglia; neurodegeneration

DOI 10.15252/emmm.201810248 | Received 26 December 2018 | Revised 21 March 2019 | Accepted 3 April 2019 | Published online 23 April 2019

EMBO Mol Med (2019) 11: e10248

See the Glossary for abbreviations used in this article.

Introduction

The innate immune system is a rapid and coordinated cellular defense response that aims to eliminate the threat posed by both sterile and infectious insults. Recognition of these pathogenic agents is mediated by pattern recognition receptors (PRRs) that sense pathogen-associated molecular patterns (PAMPs) and host- or environment-derived danger-associated molecular patterns (DAMPs). In the central nervous system (CNS), these PRRs are primarily expressed by microglia, astrocytes, and macrophages, but also oligodendrocytes, neurons, and endothelial cells express a repertoire of PRRs (Lampron et al, 2013; Walsh et al, 2014). PRRs can either be membrane-bound, as is the case for the Toll-like receptors (TLRs), to sense signals in the extracellular environment or in the endosome, or they can be intracellular, as with the nucleotide-binding domain and leucine-rich repeat-containing receptors (NLRs) and AIM2-like receptors (ALRs). An important subgroup of cytosolic PRRs that includes members of the NLR and ALR families as well as the tripartite motif (TRIM) family member pyrin critically contributes to the innate immune response by assembling so-called “inflammasomes”.

General concepts of inflammasome biology

Inflammasomes are cytosolic multiprotein complexes which upon assembly activate the pro-inflammatory caspase-1 (see Glossary) that is responsible for the maturation and secretion of the inflammatory cytokine IL-1\(\beta\) and IL-18, and additionally induce pyroptosis (Lamkanfi & Dixit, 2014; Broz & Dixit, 2016). Briefly, inflammasome-inducing stimuli trigger the oligomerization of PRR proteins and the recruitment of pre-existing procaspase-1zymogens into the complex, leading to their proximity-induced autoactivation to generate active caspase-1. Consequently, caspase-1 will cleave the biologically inactive pro-peptides pro-IL-1\(\beta\) and pro-IL-18 into mature cytokines which are then secreted by the cell. Next to its role in the maturation of pro-IL-1\(\beta\) and pro-IL-18, caspase-1 can also induce a pro-inflammatory form of cell death, pyroptosis, that features early plasma membrane rupture, thereby releasing the soluble intracellular fraction that fuels the inflammatory response (Lamkanfi & Dixit, 2012, 2014). Central in this process is the executioner protein gasdermin D (GSDMD)—a substrate of murine caspase-1 and caspase-11, and human caspase-1, caspase-4, and caspase-5—the amino-terminal domain of which upon cleavage oligomerizes and perforates the plasma membrane to induce cell swelling and osmotic lysis (Shi et al, 2017) (Fig 1).

One way to classify inflammasome complexes is based on the receptor that initiates signaling (Lamkanfi & Dixit, 2012). The core inflammasome components consist of the cytosolic NLR, ALR,
pyrin receptors, the adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1. ASC is composed of a pyrin domain (PYD) and a caspase recruitment domain (CARD) and functions as an adaptor that links the PYD of the NLR or pyrin and the CARD of procaspase-1 (Fig 2). Some inflammasomes, such as NLRC4 and NLRP1b, do not require ASC and may directly recruit procaspase-1 through their respective CARDs, although under wild-type conditions ASC does contribute to optimal caspase-1 activation and efficient secretion of IL-1β and IL-18 (Broz et al, 2010; Guey et al, 2014; Van Opdenbosch et al, 2014). Assembly and activation of inflammasomes requires detection of specific signals: Murine Nlrp1b responds to Bacillus anthracis lethal toxin (LeTx) (Boyden & Dietrich, 2006); NLRC4 detects intracellular flagellin and components of type III secretion systems (T3SS) of bacterial pathogens (Franchi et al, 2006; Miao et al, 2006, 2010); AIM2 physically binds cytosolic double-stranded DNA (dsDNA) (Hornung et al, 2009); and pyrin indirectly responds to toxins that covalently inactivate the small GTPase RhoA (Xu et al, 2014). NLRP3, the most widely studied inflammasome, responds to a broad spectrum of activating stimuli that includes a suite of bacterial, fungal, and viral PAMPs, DAMPs such as ATP and uric acid crystals, and crystalline and aggregated substances such as asbestos, silica, and amyloid-β fibrils (Lamkanfi & Dixit, 2012). NLRP3 activation is unique in the sense that it involves a two-step process. A first signal, or priming signal, results in the NF-κB-dependent transcriptional upregulation of NLRP3 and pro-IL-1β, but also controls post-translational modifications of NLRP3 as highlighted by the mapped ubiquitin and phosphorylation sites on NLRP3 (Yang et al, 2017). This is followed by a second “activation” signal that induces the oligomerization and activation of the NLRP3 inflammasome (Fig 1). Besides canonical NLRP3 inflammasome signaling, the non-canonical NLRP3 inflammasome pathway involves activation of caspase-11 (or its human orthologs caspase-4 and caspase-5) by
cytosolic LPS, and the induction of pyroptosis through the cleavage of GSDMD and the release of high mobility group box 1 protein (HMGB1) and IL-1α (Lamkanfi & Dixit, 2014; Shi et al., 2017). Apart from AIM2 and the NAIP/NLRC4 complexes, the common secondary messengers or physical ligands that bind and trigger inflammasome assembly await discovery.

Inflammasomes and the central nervous system

IL-1β and IL-18 have important functions in the CNS, and many cell types in the brain express their cognate receptors that initiate inflammatory signaling cascades that may contribute to neuronal injury and cell death (Allan et al., 2005; Alboni et al., 2010). Hence, increased levels of IL-1β and IL-18 are often observed upon CNS infection, brain injury, and neurodegenerative diseases (Heneka et al., 2014, 2018). IL-1β and IL-18 are also important for physiological functions in the CNS and have been shown to participate to processes of cognition, learning, and memory (Tsai, 2017). Pyroptosis additionally contributes to inflammasome-driven pathology through the release of other inflammatory mediators and DAMPs. Apoptosis and necroptosis are additional cell death modes that have been shown to promote neuroinflammation and neuronal degeneration in several neurodegenerative pathologies, including multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease (Zhang et al., 2017; Yuan et al., 2019).

Figure 1. Inflammasome activation and signaling.

Inflammasomes assemble in a stimulus-specific manner. Different DAMPs and PAMPs are able to induce NLRP3, while NLRP1b responds to Bacillus anthracis lethal toxin, NLRC4 recognizes bacterial flagellin and/or the type III secretion system of bacterial pathogens, AIM2 is specifically activated by dsDNA, and pyrin recognizes the inactivation of RhoA by toxins and effector proteins. Activation of the NLRP3 inflammasome involves a two-step mechanism. The priming signal is detected by membrane-bound PRRs, including TLRs and C-type lectin receptors (CLRs) and induces NF-κB-dependent transcription of NLRP3 and pro-IL-1β precursor protein, and controls post-translational modifications that license NLRP3 activation. The second activation signal is necessary for inflammasome formation, depending on the oligomerization and subsequent activation of procaspase-1. Active caspase-1 then cleaves pro-IL-1β and pro-IL-18 to their mature forms IL-1β and IL-18 which get secreted. In addition, caspase-1 can cleave gasdermin D, releasing its N-terminal fragment which translocates to the plasma membrane inducing pore formation and pyroptotic cell death. In contrast to NLRP3, other inflammasome receptors do not need this initial priming signal to induce inflammasome activation and cytokine release.
Figure 2. Domain structure of inflammasomes.
A subset of NLRs and ALRs can trigger the formation of inflammasomes. NLR family members have a nucleotide-binding and oligomerization domain (NACHT/NBD), as well as leucine-rich repeat (LRR) motifs, typically located in the center and carboxy terminus of the NLR proteins, respectively. The NACHT motif is usually flanked by an additional amino-terminal domain, either CARD or PYD, and these domains are used for further sub-classification of inflammasomes. These domains allow the recruitment of adaptor and effector proteins to the inflammasome signaling complex. The NLR gene family consists of 22 human members and 34 murine members, many of which the function is not always clear (Lamkanfi & Dixit, 2012; Broz & Dixit, 2016). In addition to the NLR-containing inflammasomes, the ALR family member AIM2 can also assemble an inflammasome complex. AIM2 is characterized by an amino-terminal PYD domain and one or two DNA-binding HIN200 domains (Hornung et al, 2009). Pyrin, also known as TRIM20, features a PYD domain, two B-boxes, and a coiled-coil domain, whereas the human pyrin also has an additional C-terminal B30.2 domain. ASC is the critical adaptor protein for many inflammasome complexes and is composed of CARD and PYD domains, the latter being necessary for homotypic interaction with a PYD-containing inflammasome sensor (NLRP3, AIM2). Procesase-1 features a CARD domain, in addition to its caspase domain, and homotypic CARD interactions result in direct or indirect (via ASC) recruitment of procesase-1 to the inflammasome complex. Inflammasome activation involves ASC and procesase-1 recruitment, resulting in ASC oligomerization into a macromolecular aggregate, known as an ASC speck (Broz & Dixit, 2016).

Although inflammasome signaling in the CNS is mainly attributed to microglia, the key innate immune cells of the brain, expression of inflammasome components has also been reported in other cell types of the CNS, including neurons (Kaushal et al, 2015), astrocytes (Freeman et al, 2017), perivascular CNS macrophages (Kawana et al, 2013), oligodendrocytes (Mckenzie et al, 2018), and endothelial cells (Gong et al, 2018) (Fig 3). However, current understanding of inflammasome activation in microglia and its role in CNS inflammation and disease is still fragmentary and primarily based on in vitro studies with primary microglia and microglial cell lines, and in vivo studies with transgenic knockout mice that lack expression of specific inflammasome components throughout the body. More appropriate research tools that allow CNS-specific inflammasome targeting are needed to investigate the relative contribution of local inflammasome signaling in specific brain cell types to overall CNS pathology. Furthermore, evidence for inflammasome activation in patients with neurodegenerative disease often relies on detection of higher IL-1β transcript levels and/or increased gene and protein expression of inflammasome components. However, increased expression levels of these NF-κB responsive genes are largely indicative of an ongoing inflammatory response rather than direct support for inflammasome engagement. We here review the current knowledge on the relevance of inflammasome activation for the most common neurodegenerative pathologies (Fig 3 and Table 1) and highlight emerging strategies for the treatment of inflammasome-driven diseases. Although inflammasome activation is also central to the pathology of many CNS infectious diseases, such as Zika, HIV, and West Nile virus, and bacterial infections that induce meningitis (Walsh et al, 2014; Mamik & Power, 2017; Heneka et al, 2018), these conditions are outside the scope of this review.

Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the CNS. MS is characterized by a compromised blood–brain barrier (BBB) that leads to immune cell infiltration from the periphery and local microglia and astrocyte activation, which together promote inflammation, demyelination, and neurodegeneration (Baecher-Allan et al, 2018). Experimental autoimmune encephalomyelitis (EAE) is a widely used rodent model of MS (Ransohoff, 2012), and both IL-1β and IL-18 were shown to critically contribute to EAE (Sutton et al, 2006; Gris et al, 2010; Lévesque et al, 2016). Most studies on the involvement of inflammasomes in MS have focused on the peripheral immune response that is shaped by lymphocytes and macrophages that enter the CNS during MS pathology. Caspase-1, IL-18, and IL-1β are upregulated in peripheral blood mononuclear cells (PBMCs) and cerebrospinal fluid (CSF) of MS patients, as are levels of the NLRP3 inflammasome-activating DAMPs ATP and uric acid (Inoue & Shinohara, 2013; Mamik & Power, 2017). Moreover, caspase-1 expression was shown to be elevated in acute and chronic demyelinating lesions (Voet et al, 2018), and caspase-1 and ASC have recently been proposed as candidate biomarkers for MS onset (Keane et al, 2018).

The role of the NLRP3 inflammasome in EAE-associated T-cell priming and trafficking into the CNS is supported by the analysis of NLRP3, caspase-1, and ASC knockout mice (Furlan et al, 1999; Gris et al, 2010; Inoue et al, 2012a). Moreover, the pharmacological NLRP3 inflammasome inhibitor MCC950/CRID3 was shown to suppress IL-1β production and attenuate EAE severity in wild-type mice (Coll et al, 2015). Similarly, pharmacological blockade of
caspase protease activity with Z-Val-Ala-DL-Asp-fluoromethylketone or the inflammatory caspase prodrug VX-765 reduced EAE symptoms in mice (Furlan et al., 1999; Mckenzie et al., 2018). Interestingly, IFNβ, the first line treatment for MS, is only effective in an NLRP3 inflammasome-dependent EAE subtype, whereas NLRP3-independent EAE could not be reversed by IFN-β therapy (Inoue et al., 2012b, 2016). We recently provided direct genetic evidence for the relevance of inflammasome signaling in microglia and border-associated macrophages during EAE (Voet et al., 2018). The anti-inflammatory protein A20 has been shown to negatively regulate NLRP3 inflammasome activation (Vande Walle et al., 2014), and deletion of A20 in microglia and CNS macrophages exacerbated EAE in mice due to NLRP3 hyperactivation that resulted in increased IL-1β secretion and CNS inflammation (Voet et al., 2018). CNS-intrinsic inflammasome activation was further reported in another study that showed caspase-1- and GSDMD-mediated pyroptosis in microglia, as well as in myelin-forming oligodendrocytes in the CNS of MS patients and EAE mice (Mckenzie et al., 2018).

The relevance of the NLRP3 inflammasome to MS has also been demonstrated in the model of cuprizone-induced demyelination, in which NLRP3-deficient mice presented delayed demyelination,
oligodendrocyte loss, and neuroinflammation (Jha et al., 2010). Additional support was provided by similar observations in caspase-1 and IL-18 knockout mice, which unlike IL-1β knockout mice showed protection (Jha et al., 2010). Moreover, IL-1β and IL-18 had a differential effect on the process of remyelination after cuprizone treatment, demonstrating a delay in remyelination in IL-1β knockout mice, whereas accelerated remyelination was seen in IL-18 knockouts (Jha et al., 2010).

Inflammasome activation in stroke

Neuroinflammation plays a crucial pathological role in stroke, and IL-1β has been identified as a key cytokine in stroke pathology. So far, four distinct inflammasomes have been implicated in stroke, viz. NLRP1, NLRP3, NLRC4, and AIM2 (Barrington et al., 2017). Additionally, early studies implicated caspase-11 in middle cerebral artery occlusion (MCAO), a mouse model of stroke (Kang et al., 2012).
Expression levels of NLRP3 and NLRP1, as well as cleavage products of caspase-1, IL-1β, and IL-18, were shown to be elevated in postmortem brain tissue of stroke patients (Fann et al., 2013). Studies with pharmacological inhibitors of inflammatory caspases and analysis of caspase-1-deficient mice—that were later shown to also lack caspase-11 expression (Kayagaki et al., 2011)—showed protection in experimental models of stroke (Friedlander et al., 1997; Hara et al., 1997; Schielke et al., 1998; Rabuffetti et al., 2000; Ross et al., 2007). In agreement, mice deficient in both IL-1α and IL-1β exhibited dramatically reduced ischemic infarct volumes in transient MCAO (Boutin et al., 2001), whereas IL-18-deficient mice did not show protection in this model (Wheeler et al., 2003). NLRP3 deficiency in mice, treatment with the NLRP3 inflammasome inhibitor MCC950/CRID3, and intracerebroventricular injection of NLRP3 siRNAs all ameliorated clinical outcomes in experimental models of stroke (Ma et al., 2014; Yang et al., 2014; Yuan et al., 2015; Ismael et al., 2018b). Also, NLR4C- and AIM2-deficient mice were shown to have significantly smaller infarct volumes compared to wild-type mice subjected to tMCAO, with was associated with strongly reduced microglia cell activation and leukocyte recruitment to the infarct site (Denes et al., 2015). Finally, an expression analysis in the peri-infarct zone of transient MCAO rats revealed elevated levels of the inflammasome components NLRP1, NLRP3, AIM2, NLR4C, and ASC (Lammerding et al., 2016), consistent with the potential activation of multiple inflammasomes in stroke.

**Inflammasome activation in traumatic brain and spinal cord injury**

Patients with traumatic brain injury (TBI) have significantly higher levels of inflammasomes markers in their CSF, including ASC, caspase-1, NLRP1, and NLRP3 (Adamczak et al., 2012; Wallisch et al., 2017). However, NLRP1b and ASC knockout mice did not show any improvement in motor recovery or lesion volume in conditions of TBI, compared to control mice, although their levels of IL-1β were reduced (Brickler et al., 2016). NLRP3 expression localizing to neurons, microglia, and astrocytes was also detected in experimental TBI (Liu et al., 2013a), and NLRP3-deficient mice as well as pharmacological blockade of NLRP3 activation were shown to improve recovery from TBI (Irrera et al., 2017). Treatment with IL-1β neutralizing antibodies also was shown to improve the cognitive outcome following TBI (Clausen et al., 2009). In contrast to IL-1β levels, which rapidly increase after TBI, IL-18 levels gradually increase over several days, suggesting that IL-1β may be involved in the early phase of TBI, while IL-18 may contribute to pathogenesis at later phases of the disease. In agreement, IL-18 inhibition resulted in improved neurologic recovery after 7 days with little effect on the early response being observed immediately after injury (Yatsiv et al., 2002).

Similar to TBI, spinal cord injury (SCI) induced higher levels of NLRP1, ASC, caspase-1, IL-1β, and IL-18 in mice, and therapeutic neutralization of ASC was proposed to result in tissue sparing and functional improvement due to reduced inflammasome activation in neurons (de Rivero Vaccari et al., 2008). Furthermore, expression of heme oxygenase-1 was shown to suppress NLRP1 inflammasome activation and neuronal cell death, and lead to improved functional recovery after SCI (Lin et al., 2016). Also, enhanced NLRP3 expression can be demonstrated in SCI, predominantly in neurons, but also in microglia and astrocytes (Zendedel et al., 2016).

**Inflammasome activation in Alzheimer’s disease**

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder and is characterized by progressive memory deficits and cognitive impairment (Sala Frigerio & De Strooper, 2016). AD pathology is dominantly explained by the amyloid hypothesis, which suggests that the increasing extracellular deposition of misfolded amyloid-beta (Aβ) is the primary cause of the disease. Although there is overwhelming evidence for a pathogenic role for Aβ in AD, neuroinflammation is increasingly regarded as another key component that actively contributes to AD pathology (De Strooper & Karran, 2016; Sala Frigerio & De Strooper, 2016). Neuroinflammation in AD is primarily driven by the CNS-resident microglia population (Sarlis & Heneka, 2017; Shi & Holtzman, 2018). Although it is recognized that microglia may exert benign and reparative activities in AD through the phagocytic removal of Aβ deposits, the accumulation of Aβ may also prime microglial cells and promote their activation and production of inflammatory mediators. Moreover, upon Aβ accumulation, microglial cells may become progressively impaired in their ability to phagocytose Aβ (Sarlis & Heneka, 2017; Shi & Holtzman, 2018). Furthermore, a microglial inflammatory state would also impact on other CNS-resident cells and result in synaptic dysfunction and neuronal damage.

Many recent studies have implicated inflammasomes in the development of AD. Elevated expression of IL-1β has been reported in microglia that surround Aβ plaques of AD patients (Griffin et al., 1989; Simard et al., 2006). Additionally, gene expression analysis of cultured PBMCs from AD patients revealed higher expression of NLRP3, ASC, caspase-1, and caspase-5 as well as the cytokines IL-1β and IL-18 (Saresella et al., 2016). The expression levels of NLR4C and ASC were also found significantly elevated in brain samples of a subgroup of sporadic AD patients (Liu & Chan, 2014). Finally, genetic variants of NLRP1 have been associated with AD risk (Pontillo et al., 2012), and the amount of NLRP1 immunopositive neurons was strongly increased in AD brain (Kaulshal et al., 2015).

In *in vitro* studies have shown that fibrillar Aβ activates the NLRP3 inflammasome when phagocytosed by microglia, leading to activation of caspase-1 and release of IL-1β (Halle et al., 2008). NLRP3 inflammasome activation has also been documented in *in vivo* in the transgenic APP/PS1 mouse model of AD, and deficiency in NLRP3 significantly ameliorated spatial memory deficits and hyperactive behavior in these mice, which was associated with reduced hippocampal and cortical Aβ deposition, smaller plaque volumes, decreased levels of pro-inflammatory cytokines, and improved microglial phagocytic ability (Heneka et al., 2013). Similar results were obtained in APP/PS1 mice that were deficient in caspase-1 (Heneka et al., 2013). Inhibition of the NLRP3 inflammasome by MCC950/CRID3 also promoted amyloid-β clearance and ameliorated cognitive function in APP/PS1 mice (Dempsey et al., 2017). Indirect inhibition of NLRP3 inflammasome activation by clinically approved fenamate non-steroidal anti-inflammatory drugs that target cyclooxygenase enzymes and volume-regulated anion channels (VRAC) also was shown to suppress microglia-mediated neuroinflammation and memory loss in 3×TgAD mice (Daniels et al., 2000).
Finally, pharmacological inhibition of caspase-1 activity by VX-765 reduced amyloid-β accumulation, brain inflammation, and cognitive impairment (Flores et al., 2018). Collectively, these findings suggest that misfolded Aβ activates the microglial NLRP3 inflammasome, which triggers the release of pro-inflammatory factors that perpetrate a chronic neuroinflammatory environment and promote AD pathology. In addition, NLRP3 inflammasome activity also results in the extracellular release of micrometer-sized ASC particles that may function as danger signals and alert surrounding macrophages (Baroja-Mazo et al., 2014). These ASC specks were shown to physically bind to Aβ to seed and spread Aβ pathology in a prion-like manner by promoting misfolded protein aggregation and plaque formation in the APP/PS1 AD model (Venegas et al., 2017).

A pathogenic role for IL-1β in AD has been demonstrated in mice with a deficiency in IL-1 receptor antagonist (IL-1ra), which resulted in increased vulnerability to intracerebroventricular injection with human oligomeric Aβ1–42 (Craft et al., 2005). Another study showed that IL-1β injection in the cerebral hemisphere increases Aβ-APP protein levels in wild-type mice (Sheng et al., 1996). In contrast, sustained hippocampal IL-1β overexpression in APP/PS1 mice was shown to reduce plaque pathology, an observation that might be explained by the increased phagocytic activity of microglia and macrophages (Shaftel et al., 2007). Similar observations were done in 3xTgAD mice, but tau phosphorylation was also increased in these mice, demonstrating the complex role of IL-1 signaling in AD (Ghosh et al., 2013). IL-1R1 deficiency in mice had no effect on Aβ deposition in Tg2576 AD mice (Das et al., 2006). Similarly, IL-1β deletion did not confer a protective effect in APP/PS1 mice (Tzeng et al., 2018). However, these mice were shown to be highly susceptible to grand-mal seizures and exhibited increased excitatory synaptic proteins and dendritic spine density, an imbalance which leads to a higher basal excitatory synaptic transmission (Tzeng et al., 2018). Therefore, IL-1β may have an unexpected role in controlling neuronal activity.

Although the focus has been on the role of NLRP3 in AD, the role of other inflammasomes has also been characterized in the context of AD. The AIM2 inflammasome was shown to increase Aβ deposition, microglia activation, and cytokine production, but does not affect behavior or memory in transgenic 5xFAD mice (Wu et al., 2017). NLRP1 knockdown in APP/PS1 mice was shown to result in significantly reduced neuronal pyroptosis and to rescue cognitive impairments (Tan et al., 2014). Finally, the NLRC4 inflammasome was shown to enhance neuronal Aβ levels through activated pro-inflammatory astrocytes (Liu & Chan, 2014).

**Inflammasome activation in amyotrophic lateral sclerosis**

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is caused by the progressive loss of upper and lower motor neurons and leads to muscle weakness and wasting (Taylor et al., 2016). Twenty percent of familial ALS cases are caused by mutations in the gene that encodes superoxide dismutase 1 (SOD1), and many experimental models of ALS rely on expression of mutant SOD1. Deficiency in caspase-1 and IL-1β, as well as treatment with the recombinant IL-1 receptor antagonist anakinra, all significantly extended the lifespan of mutant SOD1 transgenic animals (Meissner et al., 2010). Consistently, the expression of NLRP3, NLRC4, AIM2, and caspase-1 activation has been demonstrated in neural tissue of mutant SOD1 transgenic animals (Pasinelli et al., 1998; Johann et al., 2015; Guglielmi et al., 2018), and mutant SOD1 was shown to activate caspase-1 and IL-1β in microglia (Meissner et al., 2010; Lehmann et al., 2018). Increased caspase-1 levels have also been detected in serum of ALS patients (Ilzecka et al., 2001), and analysis of postmortem spinal cord tissue showed increased NLRP3, ASC, caspase-1, and IL-18 expression levels, with spinal cord astrocytes identified as the main NLRP3 inflammasome-expressing cell type (Johann et al., 2015). However, clinical studies with anakinra in ALS patients have not shown a significant reduction in disease progression (Maier et al., 2015), suggesting that inflammasome activation does not play a major role in ALS, or that the pathology is driven by IL-1α or by DAMPs via pyroptosis.

**Inflammasome activation in Parkinson’s disease**

Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra pars compacta. Lewy bodies are pathological hallmarks of the disease that predominantly consist of intra-neuronal aggregates of fibrillar α-synuclein (Przedborski, 2017). Analysis of the serum of PD patients revealed increased levels of IL-1β and caspase-1 (Zhou et al., 2016), and elevated IL-1β levels were observed in the striata of PD patients (Mogi et al., 1994). The midbrain of A53T transgenic mice, which model PD based on the overexpression of mutant human A53T α-synuclein, also contained increased IL-1β concentrations (Zhou et al., 2016). Chronic expression of IL-1β in the substantia nigra of rats by a recombinant adenovirus expressing IL-1β was shown to induce progressive death of dopaminergic neurons and resulted in motor impairments (Ferrari et al., 2006). However, most of the evidence linking PD to inflammasome signaling comes from in vitro studies, and the importance of inflammasomes for the disease is not completely understood. α-Synuclein was shown to trigger activation of the NLRP3 inflammasome in human monocytes and BV2 microglial cells (Codolo et al., 2013; Gustot et al., 2015; Zhou et al., 2016), but not in primary microglia (Gustin et al., 2015). In vivo, microinjection of the caspase-1 inhibitor Ac-YVAD-CMK was shown to reduce the expression of NLRP3 inflammasome signaling proteins and improve the number of dopaminergic neurons in MPTP-treated PD mice (Mao et al., 2016). In agreement, NLRP3 knockout mice were resistant to the loss of nigral dopaminergic neurons induced by treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which was associated with a reduction in caspase-1 activation and IL-1β and IL-18 secretion (Yan et al., 2015). Recently, caspase-1 was shown to cleave α-synuclein in vitro, generating an aggregation-prone protein that was toxic to cultured neurons (Wang et al., 2016). Finally, mutations in Parkin, PARK2, PARK6, and PINK1 have been identified in patients with autosomal recessive early-onset PD, and microglia and macrophages from PARK2 and PINK1 knockout mice and patients with PARK2 mutations have been shown to display an exacerbated NLRP3 inflammasome response, possibly due to impaired expression of the anti-inflammatory protein A20 that negatively regulates NLRP3 inflammasome activation (Mouton-Liger et al., 2018).
Inflammasome activation in prion disease

Prion diseases are a group of rapidly progressive neurodegenerative disorders caused by misfolded aggregated infectious prion proteins (PrP) (Sigurdson et al., 2018). IL-1β levels are increased in the CSF of patients with Creutzfeldt–Jakob disease (CJD) (Van Everbroeck et al., 2002), and IL-1β and cleaved caspase-1 levels were reported to be upregulated in the brains of scrapie-infected mice (Schultz et al., 2004). Stimulation of microglia with an amyloidogenic PrP peptide induced NLRP3 activation and IL-1β secretion in vitro (Shi et al., 2012). Stimulation of microglia with PrP fibrils was also shown to induce toxicity in neurons (Hafner-Bratkovic et al., 2012). Mechanistically, NLRP3 inflammasome activation was suggested to negatively regulate autophagy in microglia, thereby contributing to neurodegeneration (Lai et al., 2018). Inhibition of IL-1R signaling with anakinra was shown to reduce seizure susceptibility in a CJD mouse model (Bertani et al., 2017). However, genetic ablation of NLRP3 or ASC in mice did not affect prion pathogenesis, suggesting that the NLRP3 inflammasome does not play a significant role in prion disease (Nuvolone et al., 2015).

Inflammasome activation in Huntington’s disease

Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disease that is caused by the expansion of a trinucleotide CAG repeat in the 5’ coding region of the huntingtin gene, leading to the expression of an abnormal protein that gradually damages cells in the brain (Caron et al., 2018). Caspase-1 activation can be detected in the brains of HD patients and in mouse models of HD, and inhibition of caspase-1 was shown to slow down disease progression in the R6/2 mouse model of HD (Ona et al., 1999). Mechanistically, caspase-1 was shown to cleave mutant and wild-type huntingtin in vitro (Wellington et al., 1998) and in vivo (Ona et al., 1999), potentially contributing to the neurodegeneration seen in HD. Similarly, treatment with the tetracycline derivative minocycline was shown to delay disease progression by inhibition of caspase-1 and caspase-3 expression (Chen et al., 2000).

Pharmacological targeting of inflammasomes

The central role of inflammasomes in neuroinflammatory responses, in particular NLRP3, makes it an attractive drug target for neurodegenerative diseases. Currently approved therapies in the clinic target the downstream effector cytokines released by inflammasome activation, such as anakinra (IL-1 receptor antagonist), canakinumab (IL-1β neutralizing antibody), and rilonacept (soluble decoy receptor for IL-1β and IL-1α) (Dinarello et al., 2012). While valuable in treating autoinflammatory diseases (Van Gorp et al., 2019), these IL-1 inhibitors do not prevent pyroptosis and IL-18-driven immune activation. The need for subcutaneous administration of these biological agents represents another drawback of these biological agents (Moran et al., 2013; Rossi-Semerano et al., 2015), especially in the case of anakinra, which requires daily injections due to a short half-life of around 4–6 h (Granowitz et al., 1992). Moreover, constitutive neutralization of IL-1β-driven signaling increases the risk for infections, as observed in the recent CANTOS trial (Ridker et al., 2017). Finally, the concentration of anakinra in CSF of healthy non-human primates did not surpass 0.2–0.3% of the peripheral serum concentration, demonstrating poor penetration of the BBB (Fox et al., 2010). These observations urge for the development of small molecule inflammasome antagonists with improved pharmacokinetic properties and efficacy, and that are able to cross the BBB.

Several small molecule inhibitors that target the inflammasome components caspase-1, NLRP3, and GDMD have been reported (Table 2). Since caspase-1 activation is common to all inflammasome complexes, caspase-1 inhibition would serve as a pan-inflammasome inhibitory strategy, while compounds targeting NLRP3 have a narrower selectivity profile. Targeting the inflammasome adaptor ASC would have an intermediate selectivity profile; however, compounds that target ASC have not been reported to date (Mangan et al., 2018). A number of NLRP3 inhibitory compounds have been identified and validated in a suite of disease models (Table 2). However, for most agents it is not known whether they directly target NLRP3 or indirectly act on the pathway via other mechanisms, hampering clinical development of these molecules (Mangan et al., 2018). To date, only very few compounds targeting NLRP3 or caspase-1 have entered clinical trials. RP-1127, an intravenous formulation of the NLRP3 inflammasome inhibitor glyburide (Lamkanfi et al., 2009), is being tested in a clinical trial for stroke (EudrACT 2017-004854-41) after a positively evaluated pilot study (ClinicalTrials.gov: NCT01268683) (Sheth et al., 2014). RP-1127 is also being tested in a clinical trial for TBI (ClinicalTrials.gov: NCT01454154). In addition, the caspase-1 inhibitor VX-765 entered a phase II clinical trial for use in epilepsy (ClinicalTrials.gov: NCT01048255) and psoriasis (ClinicalTrials.gov: NCT00205465), but further development has been discontinued (Mackenzie et al., 2010). The encouraging activity of small molecule NLRP3 inflammasome antagonists in preclinical studies warrants the development of inflammasome-targeting therapies for clinical use.

Pyroptosis is emerging as another key mechanism that contributes to inflammasome-driven pathology in metabolic, autoimmune, and neurodegenerative diseases. Cleavage of GSDMD by the inflammatory caspase-1 and caspase-11 (mouse), or caspase-1, caspase-4, and caspase-5 (human) releases an amino-terminal pore-forming GSDMD domain that oligomerizes and inserts in the plasma membrane, inducing membrane rupture and leakage of the cytosolic contents (Vande Walle & Lamkanfi, 2016). Hence, GSDMD inhibition has been proposed as a novel therapeutic strategy to prevent inflammasome-driven pathology in different diseases. Pyroptosis has recently been shown to be the critical mechanism of IL-1β-mediated systemic pathology in the autoinflammatory disease Familial Mediterranean Fever (FMF), which is caused by missense mutations in Mefv that activates the pyrin inflammasome (Kanneganti et al., 2018). Similarly, GSDMD was shown to control inflammasome-driven pathology in neonatal-onset multisystem inflammatory disease (NOMID), which is caused by activating mutations in the inflammasome sensor NLRP3 (Xiao et al., 2018). Indeed, FMF knockin mice and NOMID mice were shown to be fully protected from developing the respective autoinflammatory syndromes when crossed into a Gsdmd-deficient background (Kanneganti et al., 2018; Xiao et al., 2018). GSDMD was also demonstrated to play a key role in the pathogenesis of steatohepatitis by controlling cytokine secretion, and Gsdmd knockout mice exhibit decreased severity of steatosis and inflammation in a high-fat
| Compounds                                               | Benefit (+)/detriment (-)                                                                 | Neurodegenerative disease model                                                   |
|---------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| **Caspase-1 inhibitors**                                |                                                                                          |                                                                                   |
| VX-765 and VX-740                                        | (--) No further development after phase II clinical trial for use in epilepsy and psoriasis | Alzheimer disease (Flores et al, 2018) EAE (Mckenzie et al, 2018)                  |
| **NLRP3 inflammasome inhibitors**                       |                                                                                          |                                                                                   |
| Glyburide                                               | (+) Specific for NLRP3 inflammasomes; significantly delays LPS-induced mortality (Lamkanfi et al, 2009); (-) High dosage required (Marchetti et al, 2014); cardiovascular side effects (Riddle, 2003) | TBI (Simard et al, 2012) Ischemic stroke (Simard et al, 2012)                     |
| CP-412,245 and CP-424,174                               | (+) Oral administration of CP-424,174 selectively blocks IL-1 production in mice (Perregaux et al, 2001) |                                                                                   |
| CRID1 and CRID2                                          | (--) No in vivo evidence                                                                 |                                                                                   |
| **Sulfonylurea-based compounds**                        |                                                                                          |                                                                                   |
| MCC950 (also known as CRID3 or CP-456,773)              | (+) NLRP3 inflammasome specific (Coll et al, 2015); inhibits NLRP3 activation by all known stimuli (Mangan et al, 2018); (--) Precise molecular target unknown | Alzheimer disease (Dempsey et al, 2017) EAE (Coll et al, 2015)                     |
| 16673-34-0                                              | (+) Lacks cyclohexylurea group responsible for hypoglycemic activity; prevents NLRP-mediated myocardial injury (Marchetti et al, 2014) | TBI (Israel et al, 2018a; Xu et al, 2018) Stroke (Israel et al, 2018b; Ren et al, 2018) |
| Hybrid molecules (combining MCC950 and glyburide)       | (--) Moderately effective at inhibiting NLRP3 compared to MCC950 (Hill et al, 2017)         |                                                                                   |
| **Fenamate classes of NSAIDs**                          |                                                                                          |                                                                                   |
| Flufenamic and mefenamic acid                           | (+) Inhibits NLRP3 by blocking VRACs (Daniels et al, 2016); (--) Lack of specificity, inhibits multiple inflammatory nodes (Daniels et al, 2016) | Alzheimer disease (Daniels et al, 2016)                                            |
| **Michael acceptors**                                   |                                                                                          |                                                                                   |
| Parthenolide                                             | (--) No suitable pharmacological properties (Baldwin et al, 2016); inhibits NF-κB-dependent signaling (Saadane et al, 2007) | Stroke (Dong et al, 2013)                                                         |
| BAY 11-7082                                             | (--) Not specific; inhibits NF-κB-dependent signaling (Lee et al, 2012)                    | TBI (Irrera et al, 2017)                                                         |
| 3,4-methylenedioxy-β-nitrostyrene (MNS)                  | (--) Modest potency (Baldwin et al, 2016)                                                 |                                                                                   |
| Acrylate and acrylamide derivatives (ex. IFN58, IFN39)   | (+) Oral administration of IFN39 alleviates DNBS-induced colitis in rats (Cocco et al, 2017) |                                                                                   |
| **Novel boron compound series**                         |                                                                                          |                                                                                   |
| NBC13                                                   | (+) Significantly decreases LPS-induced IL-1β production in vivo (Baldwin et al, 2017)     |                                                                                   |
| **Other NLRP3 inhibitors**                              |                                                                                          |                                                                                   |
| Fc11a-2                                                 | (+) In vivo efficacy in DSS-induced colitis (Liu et al, 2013b)                             |                                                                                   |
| CY-09                                                   | (+) Therapeutic effect in mouse models of CAPS and type 2 diabetes (Jiang et al, 2017)     |                                                                                   |
| JC-171                                                  | (+) Treatment effective in EAE in both prophylactic and therapeutic settings (Guo et al, 2017) | EAE (Guo et al, 2017)                                                           |
| OLT-177                                                 | (+) No adverse effects in preliminary clinical testing of healthy humans (Marchetti et al, 2018) |                                                                                   |
| β-hydroxybutyrate (BHB)                                 | (--) Not specific for NLRP3; can inhibit HDACs (Youm et al, 2015)                         |                                                                                   |
| **GSDMD inhibitors**                                    |                                                                                          |                                                                                   |
| Antabuse                                                 | (+) Efficacious in sepsis models (preprint: Hu et al, 2018)                               |                                                                                   |
| Necrosulfonamide                                        | (+) Efficacious in sepsis models (Rathkey et al, 2018)                                   |                                                                                   |
diet-induced model of non-alcoholic steatohepatitis (Xu et al., 2017). Pharmacologic inhibition of GSDMD by necrosulfonamide also was efficacious in sepsis models (Rathkey et al., 2018). Finally, antabuse (disulfiram), a drug used to treat alcohol addiction, was shown to inhibit GSDMD pore formation and IL-1β secretion in human and mouse cells, and LPS-induced septic death and IL-1β secretion in mice (preprint: Hu et al., 2018). Together, these observations suggest that inhibition of GSDMD-dependent pyroptosis may also hold promise for the treatment of inflammasome-mediated neuroinflammatory pathology.

Concluding remarks and future perspectives

Although only discovered in 2002 (Martinon et al., 2002), inflammasomes are now widely regarded as central regulators of innate immunity playing an indispensable role in the host defense against stress conditions and pathogens that might be harmful to the host. However, inflammasome activation leading to excessive or prolonged inflammation can also contribute to a damaging and destructive environment resulting in the development of inflammatory diseases, including neurodegenerative diseases (Lamkanfi & Dixit, 2012).

Most research in the field has focused on the role of the NLRP3 inflammasome, largely neglecting the potential importance of other inflammasome complexes in CNS disorders. Future research will have to investigate and characterize less well-known inflammasomes and expand the understanding of inflammasome signaling and its importance for neurodegeneration. The generation of new mouse models and reagents that allow selective targeting of the inflammasome mechanisms initiated by these inflammasomes will be crucial to this end. Also, although the importance of inflammasome activation has been demonstrated in many neurodegenerative diseases and experimental model systems, their specific role in the different CNS cell types is not always clear. Most research has focused on microglia, but other brain cell types also have functional inflammasomes which may contribute to disease pathology (Walsh et al., 2014). Since most studies published so far have investigated inflammasome activation using conventional “full body” knockout mice which do not allow to specify the relevant cell types involved, cell type-specific inflammasome mutant mice will be needed to address the importance of inflammasome signaling in CNS-specific cell types, assessing their importance for cytokine production, pyroptosis, and CNS inflammation. Also, new techniques including single-cell RNA sequencing and mass cytometry, in combination with high-resolution microscopy and in vivo cell imaging, should help to get a better view on the spectrum of inflammasomes that is expressed in the different CNS-resident cell types in different (pathological) conditions.

Major progress needs to be made in translating findings from animal studies to humans. However, key differences exist between human and mouse inflammasomes. Humans have only a single NLRP1 gene, while mice have three isoforms of Nlrp1. Similarly, humans have two orthologues for caspase-11, viz. caspase-4 and caspase-5 (Lamkanfi & Dixit, 2012). More research using human cell types, eventually based on IPS technology and patient-derived material, will be needed to translate findings more effectively from rodents to the human conditions they model.

Finally, since inflammasome signaling is central to many neurodegenerative diseases, targeting their activation is regarded as a potential therapy to treat these diseases. Targeting the downstream IL-1β and IL-18 cytokines is probably not the best approach since these cytokines are needed for optimal immunity in the host. Moreover, cytokine-targeting biologics have limited capacity to penetrate the blood–brain barrier. Therefore, modulating the activity of specific inflammasome sensors and cell type-specific inflammasome targeting with small molecules will be vital in this context and may have better potential as therapies to treat patients that suffer from neurodegenerative diseases (Guo et al., 2015). Also, pyroptosis is now being identified as a critical mechanism driving inflammatory pathology, suggesting GSDMD inhibition as a potential anti-inflammatory strategy (Kanneganti et al., 2018; Mckenzie et al., 2018; Xiao et al., 2018).

Acknowledgements

S.V. is a predoctoral fellow with the Institute for the Promotion of Innovation by Science and Technology (IWT) and is supported by grants from the Charcot Foundation and the Queen Elisabeth Medical Foundation. S.S. is a predoctoral fellow with the FWO and is supported by a “Hope in Head” Rotary grant. Work in the G.V.L. laboratory is supported by research grants from the FWO, the Queen Elisabeth Medical Foundation, the CBC Banque Prize, the Charcot Foundation, the “Belgian Foundation Against Cancer”, and the “Concerted Research Actions” (GOA) of the Ghent University. M.L. is supported by European Research Council Grant 683144 (PyroPop).

Conflict of interest

The authors declare that they have no conflict of interest.

Pending issues

(i) The cell type-specific contribution of inflammasome signaling to neurodegenerative diseases, both peripheral and CNS resident.
(ii) Direct evidence for inflammasome activation and signaling in patients with neurodegenerative disease.
(iii) Characterization of the central activation mechanism and high-resolution structure of inflammasome proteins.
(iv) Development of compounds able to cross the BBB and that selectively inhibit those inflammasomes that contribute to the pathogenicity.

References

Adamczak S, Dale G, de Rivero Vaccari JP, Bullock MR, Dietrich WD, Keane RW (2012) Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome. J Neurosurg 117: 1119–1125
Alboni S, Cerva D, Sugama S, Conti B (2010) Interleukin 18 in the CNS. J Neuroinflammation 7: 9
Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5: 629–640
Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neurology 97: 742–768
Baldwin AG, Brough D, Freeman S (2016) Inhibiting the inflammasome: a chemical perspective. J Med Chem 59: 1691–1710
Baldwin AG, Rivers-Auty J, Daniels MJ, White CS, Schwalbe CH, Schilling T, Hammadi H, Jaiyong P, Spencer NG, England H et al (2017) Boron-based inhibitors of the NLRP3 inflammasome. Cell Chem Biol 24: 1321–1335.e5

Baroja-Mazo A, Martín-Sánchez F, Gómez Al, Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe J, Ruiz-Ortiz E, Antón J et al (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15: 738–748

Barrington J, Lemarchand E, Allan SM (2017) A brain in flame; do inflammasomes and pyroptosis influence stroke pathology? Brain Pathol 27: 205–212

Bertani I, Iori V, Trusel M, Maroso M, Foray C, Mantovani S, Tonini R, Vezzani A, Chiesa R (2017) Inhibition of IL-1β signaling normalizes NMDA-dependent neurotransmission and reduces seizure susceptibility in a mouse model of Creutzfeldt-Jakob disease. J Neurosci 37: 10278–10289

Boutin H, LeFevre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ (2001) Role of IL-1α and IL-1β in ischemic brain damage. J Neurosci 21: 5258–5334

Boyd ED, Dietrich WF (2006) Naip1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38: 240–244

Brickler T, Gresham K, Meza A, Coutermarsh-Ott S, Williams TM, Rothschild EM, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Baldwin AG, Freeman S et al (2016) Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun 7: 12504

Das P, Smithson LA, Price RW, Holloway VM, Levites Y, Chakrabarty P, Golde TE (2006) Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Aβ immunotherapy. J Neuroinflammation 3: 17

De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164: 603–615

Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O’Neill LAJ, Lynch MA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun 61: 306–316

Denes A, Coutts G, Lénárt N, Cruickshank SM, Pelegrin P, Skinner J, Rothwell N, Allan SM, Brough D (2019) AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc Natl Acad Sci USA 112: 4050–4055

Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633–652

Dong L, Qiao H, Zhang X, Zhang X, Wang C, Wang L, Cui L, Zhao J, Xing Y, Li Y et al (2013) Partenolide is neuroprotective in rat experimental stroke model: downregulating NF-κB, phospho-p38MAPK, and caspase-1 and ameliorating BBB permeability. Mediators Inflamm 2013: 370804

Fann DY-W, Lee S-Y, Manzano S, Tang S-C, Gelderblom M, Chanduri P, Bernreuther C, Glatzel M, Cheng Y-L, Thundyij J et al (2013) Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 4: e790

Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. Neurobiol Dis 24: 183–193

Flores J, Noel A, Foveau B, Lynham J, Leccuru C, LeBlanc AC (2018) Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nat Commun 9: 3916

Fox E, Jayapryakash N, Pham T-H, Rowley A, McCully CL, Pucino F, Goldbach-Mansky R (2010) The serum and cerebrospinal fluid pharmacokinetics of parthenolide in mice. Nat Med 652: 214–218

Franche L, Amer A, Body-Malapel M, Kanneganti T-D, Özören N, Jagirdar R, Inohara N, Vandenabeele P, Bertin J, Coyle A et al (2006) Cytosolic flagellin requires IpaB for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nat Immunol 7: 576–582

Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JP-Y et al (2017) Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem 60: 3656–3671

Codozo G, Plotegeur N, Pozzobon T, Brucalle M, Tessari I, Bubacco L, de Bernard M (2013) Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS ONE 8: e55375

Coll RC, Robertson AAB, Chae JI, Higgins SC, Muñoz-Planillo R, Insercia MC, Vetter I, Dungan LS, Monks BG, Stutz A et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21: 248–255

Craft JM, Watterson DM, Hirsch E, Van Eldik LJ (2005) Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid. J Neuroinflammation 2: 15

Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, Booth SJ, White CS, Baldwin AG, Freeman S et al (2016) Fenamate NSAIDs
Gong Z, Pan J, Shen Q, Li M, Peng Y (2018) Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/ reperfusion injury. j Neuroinflammation 15: 242
Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4: 355 – 360
Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Aroz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611 – 7615
Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, Huang M, Schneider M, Miller SD, Ting JP-Y (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Thunder and Th17 responses. j Immunol 185: 974 – 981
Guey B, Bodnar M, Maniš SN, Tardivel A, Pettrilli V (2014) Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci USA 111: 17254 – 17259
Gugliandolo A, Giacoppo S, Bramanti P, Mazzon E (2018) NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation 41: 93 – 103
Guo H, Callaway JB, Ting JP-Y (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21: 677 – 687
Guo C, Fulj JW, Jiang Y, Li X, Chojnacki JE, Wu J, Wang X-Y, Zhang S (2017) Development and characterization of a hydroxyl–sulfonamide analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem Neurosci 8: 2194 – 2201
Gustin A, Kirchmeyer M, Koncina E, Felten P, Locsfoot S, Heurtaux T, Tardivel A, Heusching P, Dostert C (2015) NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS ONE 10: e0130624
Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert J-M, Raussern V (2015) Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Biochimie 471: 323 – 333
Hafner-Bratkovič I, Benčina M, Fitzgerald KA, Golenbock D, Jeral A (2012) NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity. Cell Mol Life Sci 69: 4215 – 4228
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinecker H, Fitzgerald K, Latz E, Moore K, Golenbock D (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 9: 857 – 865
Harake H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA (1997) Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 94: 2007 – 2012
Heneka MT, Kummer MP, Stutz A, Deleka A, Schwartz S, Vieira-Saechker A, Griep A, Axt D, Remus A, Tzeng T-C et al (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674 – 678
Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14: 463 – 477
Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19: 610 – 621
Hill JR, Coli RC, Sue N, Reid JC, Dou J, Holley CL, Pelingon R, Dickinson JB, Biden TJ, Schroder K et al (2017) Sulfonyleureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors. ChemMedChem 12: 1449 – 1457
Hornung V, Ablasser A, Charrel-Dennis M, Bauermeister F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514 – 518
Hu JH, Liu X, Zhao J, Xia S, Ruan J, Luo X, Kim J, Lieberman J, Wu H (2018) Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. bioRxiv https://doi.org/10.1101/369908 [PREPRINT]
Iltzeck J, Stelmasiak Z, Dobosz B (2001) Interleukin-1β converting enzyme/ Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol Scand 103: 255 – 258
Inoue M, Williams KL, Guns MD, Shinohara ML (2012a) NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 109: 10480 – 10485
Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan J V, Miao EA, Shinohara ML (2012b) Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 5: ra38
Inoue M, Shinohara ML (2013) NLRP3 inflammasome and MS/EAE. Autoimmun Dis 2013: 859145
Inoue M, Chen P-H, Siecinski S, Li Q-J, Liu C, Steinman L, Gregory SG, Benner E, Shinohara ML (2016) An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. Nat Neurosci 19: 1599 – 1609
Irrera N, Pizzino G, Calò B, Pallio G, Mannino F, Famá F, Arcoraci V, Fodale V, David A, Francesca C et al (2017) Lack of the Nlrp3 inflammasome improves mice recovery following traumatic brain injury. Front Pharmacol 8: 459
Ismail S, Nasooshi S, Ishrat T (2018a) MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. J Neurotrauma 35: 1294 – 1303
Ismail S, Zhao L, Nasooshi S, Ishrat T (2018b) Inhibition of the NLRP3 inflammasome as a potential approach for neuroprotection after stroke. Sci Rep 8: 5971
Jha S, Srivastava SY, Brickey WJ, Iocca H, Toews A, Morrison JP, Chen VS, Gris D, Mutsushima GK, Ting JP-Y (2010) The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 30: 15811 – 15820
Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q et al (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. j Exp Med 214: 3219 – 3238
Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizzo T, Weis J, Troost D, Beyer C (2015) NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glio 63: 2260 – 2273
Kang S-J, Wang S, Hara H, Peterson EP, Namura S, Amin-Hanjani S, Huang Z, Srinivasan A, Tomaselii KJ, Thornbery NA et al (2000) Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol 149: 613 – 622
Kanneganti A, Mailiredi RKS, Saavedra PHV, Vande Walle L, Van Gorp H, Kambara H, Tillman H, Vogel P, Luo HR, Xavier RJ et al (2018) GSDMD is critical for autoinflammatory pathology in a mouse model of familial Mediterranean fever. j Exp Med 215: 1519 – 1529
Kauhal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, Ghetti B, Koller BH, LeBlanc AC (2015) Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1β production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ 22: 1676 – 1686
Pasinelli P, Borghelt DR, Houseweart MK, Cleveland DW, Brown RHJ (1998) Caspase-3 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 95: 15763–15768

Perregaux DG, McNiff P, Laliberte R, Havrylyuk N, Peurano H, Stamm E, Eggl J, Griffiths R, Dombroski MA, Gabel CA (2001) Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther 299: 187–197

Pontillo A, Catamo E, Arosio B, Mari D, Crovella S (2012) NALP1/NLRP1 genetic variants are associated with Alzheimer disease. Alzheimer Dis Assoc Disord 26: 277–281

Przedborski S (2017) The two-century journey of Parkinson disease research.

Nat Rev Neurosci 18: 251 – 259

Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M (2016) The NLRP1 inflammasome is activated in Alzheimer disease and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595–1604

Shafiel SS, Kyrkanides S, Olshchowa JA, Miller JH, Johnson RE, O’Banion MK (2007) Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595–1604

Sheng JC, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldijk LJ, Griffin WST (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 17: 761 – 766

Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM et al (2014) Pilot study of intravenus glubride in patients with a large ischemic stroke. Stroke 45: 281 – 283

Shi F, Yang L, Kouadir M, Yang Y, Wang J, Zhou X, Yin X, Zhao D (2012) The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation. J Neuroinflammation 9: 73

Shi J, Gao W, Shao F (2017) Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42: 254 – 256

Shi Y, Holtzman DM (2018) Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol 18: 759 – 772

Sigurdson CJ, Bartz JC, Glatzel M (2018) Cellular and molecular mechanisms of prion disease. Annu Rev Pathol 13: 197 – 216

Simard AR, Soulet D, Cowling G, Julien J-P, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49: 489 – 502

Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V (2012) Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab 32: 1699 – 1717

Sutton C, Brereton C, Keogh B, Mills KHG, Lavelle EC (2014) Decoding ALS: from genes to mechanism. Nature 539: 197 – 206

Tsi S-J (2017) Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions. Cytokine Growth Factor Rev 37: 89 – 97

Tszeng T-C, Hasegawa Y, Iuchi R, Cheung A, Caffrey DR, Thatcher Ej, Mao W, Germain G, Tamburro ND, Okabe S et al (2018) Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proc Natl Acad Sci USA 115: 9002 – 9007

Van Everbroeck B, Dewulf E, Pals P, Luikse U, Martin JJ, Cras P (2003) The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging 23: 59 – 64

Van Corp H, Van Opdenbosch N, Lamkanfi M (2019) Inflammasome-dependent cytokines at the crossroads of health and autoinflammatory disease. Cold Spring Harb Perspect Biol 11: pii: a028563

Van Opdenbosch N, Gurung P, Vande Walle L, Fossoul A, Kanneganti T-D, Lamkanfi M (2014) Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun 5: 1 – 14

Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P, Beyaert R, Elewaad D, Kanneganti T-D, van Log M et al (2014) Negative
regulation of the NLRP3 inflammasome by A2O protects against arthritis. Nature 512: 69 – 73

Vande Walle L, Lamkanfi M (2016) Pyroptosis. Curr Biol 26: R568 – R572

Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecher A, Schwartz S, Santarelli F, Kummer MP et al (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552: 355 – 361

Voet S, Mc Guire C, Hagemeyer N, Martens A, Schroeder A, Wieghofer P, Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Vande Walle L, Lamkanfi M (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552: 355 – 361.

Voet S, Mc Guire C, Hagemeyer N, Martens A, Schroeder A, Wieghofer P, Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Vande Walle L, Lamkanfi M (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552: 355 – 361.

Wallisch JS, Simon DW, Bayr H, Bell MJ, Kochanek PM, Clark RS (2017) Cerebrospinal fluid NLRP3 is increased after severe traumatic brain injury in infants and children. Neurocrit Care 27: 44 – 50

Walsh JC, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15: 84 – 97

Wang W, Nguyen LTT, Burak C, Chegini F, Guo F, Chataway T, Ju S, Fisher OS, Miller DW, Datta D et al (2018) Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein. Proc Natl Acad Sci USA 113: 9587 – 9592

Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158 – 9167

Wheelier RD, Boutin H, Touzani O, Luheshi GN, Takeda K, Rothwell NJ (2003) No role for interleukin-18 in acute murine stroke-induced brain injury. J Cereb Blood Flow Metab 23: 531 – 535

Wu P-J, Hung Y-F, Liu H-Y, Hsueh Y-P (2017) Deletion of the inflammasome sensor Aim2 mitigates Aβ deposition and microglial activation but increases inflammatory cytokine expression in an alzheimer disease mouse model. Neuroimmunomodulation 24: 29 – 39

Xiao J, Wang C, Yao J-C, Alippe Y, Xu C, Kress D, Civitelli R, Abu-Amer Y, Kanneganti T-D, Link DC et al (2018) Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. Proc Natl Acad Sci 116: e3000047

Xu H, Yang J, Gao W, Li L, Li P, Zhang L, Gong Y-N, Peng X, Ji XJ, Chen S et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513: 237 – 241

Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Nie Y et al (2017) Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol 68: 773 – 782

Xu X, Yin D, Ren H, Gao W, Li F, Sun D, Wu Y, Zhou S, Lyu L, Yang M et al (2018) Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury. Neurobiol Dis 117: 15 – 27

Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, Zhou R (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160: 62 – 73

Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, Shi W, Li F, Xin T, Pang Q et al (2014) NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab 34: 660 – 667

Yang J, Liu Z, Xiao TS (2017) Post-translational regulation of inflammasomes. Cell Mol Immunol 14: 65 – 79

Yatsiv I, Morganti-Kossmann MC, Perez D, Dinarello CA, Novick D, Rubinstein M, Otto V, Rancan M, Kossmann T, Redaelli CA et al (2002) Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 22: 971 – 978

Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD et al (2015) The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21: 263 – 269

Yuan B, Shen H, Lin L, Su T, Zhong S, Yang Z (2015) Recombinant adenovirus encoding NLRP3 RNAi attenuates inflammation and brain injury after intracerebral hemorrhage. J Neuroimmunol 287: 71 – 75

Yuan J, Amin P, Ofengeim D (2019) Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci 20: 19 – 33

Zenderel A, Johann S, Mehrabi S, Joghataei M, Hassanzadeh G, Kipp M, Beyer Otto VI, Rancan M, Kossmann T, Redaelli CA et al (2002) Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 22: 971 – 978

Zhang S, Tang M, Luo H, Shi C, Xu Y (2017) Necroptosis in neurodegenerative diseases: a potential therapeutic target. Cell Death Dis 8: e2905

Zhou Y, Lu M, Du R-H, Qiao C, Jiang C-Y, Zhang K-Z, Ding J-H, Hu G (2016) MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener 11: 28

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.